MX338323B - Formulacion topica oftalmica de peptidos. - Google Patents

Formulacion topica oftalmica de peptidos.

Info

Publication number
MX338323B
MX338323B MX2012007282A MX2012007282A MX338323B MX 338323 B MX338323 B MX 338323B MX 2012007282 A MX2012007282 A MX 2012007282A MX 2012007282 A MX2012007282 A MX 2012007282A MX 338323 B MX338323 B MX 338323B
Authority
MX
Mexico
Prior art keywords
topical ophthalmic
peptide formulation
ophthalmic peptide
formulation
topical
Prior art date
Application number
MX2012007282A
Other languages
English (en)
Other versions
MX2012007282A (es
Inventor
Berta Ponsati Obiols
Jimena Fernández Carneado
Marc Gómez Caminals
Ribera Jordana I Lluch
Rafael Simó Canonge
Cristina Herznández Pascual
Josep Farrera Sinfreu
Original Assignee
Bcn Peptides Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43928893&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX338323(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bcn Peptides Sa filed Critical Bcn Peptides Sa
Publication of MX2012007282A publication Critical patent/MX2012007282A/es
Publication of MX338323B publication Critical patent/MX338323B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a el uso de somatostatina o un análogo de somatostatina en la preparación de una composición tópica oftálmica seleccionada del grupo formado por colirios, pomadas y ungüentos para el tratamiento y/o prevención de una enfermedad del segmento posterior del ojo seleccionada del grupo formado por retinopatía diabética no-proliferativa, retinopatía diabética proliferativa, neovascularización de retina, retinopatía inducida por isquemia, retinopatía de la prematuridad, retinopatía de células falciformes, oclusión de la vena retinal, retinitis pigmentosa, uveítis, edema macular y edema macular cistoide mediante administración tópica ocular, donde la somatostatina o análogo de somatostatina se seleccionan del grupo formado por somatostatina-28, somatostatina-14, somatostatina-13, prosomatostatina, octreotide, lanreotine, vapreotide, pasireotide, seglitide, cortistatin y sus sales farmacéuticamente aceptables, y donde la concentración de dicha somatostatina o análogo de somatostatina en la composición está entre 1 µg/mL y 10mg/mL.
MX2012007282A 2009-12-22 2010-12-17 Formulacion topica oftalmica de peptidos. MX338323B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200931242A ES2362604B1 (es) 2009-12-22 2009-12-22 Formulación tópica oftálmica de péptidos.
PCT/EP2010/007737 WO2011076368A2 (en) 2009-12-22 2010-12-17 Topical ophthalmic peptide formulation

Publications (2)

Publication Number Publication Date
MX2012007282A MX2012007282A (es) 2012-10-15
MX338323B true MX338323B (es) 2016-04-12

Family

ID=43928893

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007282A MX338323B (es) 2009-12-22 2010-12-17 Formulacion topica oftalmica de peptidos.

Country Status (34)

Country Link
US (1) US9216208B2 (es)
EP (1) EP2515870B1 (es)
JP (1) JP5920928B2 (es)
KR (1) KR101657737B1 (es)
CN (1) CN102753153B (es)
AR (1) AR079683A1 (es)
AU (1) AU2010335595B2 (es)
BR (1) BR112012015386B8 (es)
CA (1) CA2785104C (es)
CL (1) CL2012001737A1 (es)
CO (1) CO6592047A2 (es)
CY (1) CY1117854T1 (es)
DK (1) DK2515870T3 (es)
ES (2) ES2362604B1 (es)
HK (1) HK1178049A1 (es)
HR (1) HRP20160954T1 (es)
HU (1) HUE028193T2 (es)
IL (1) IL220584A (es)
LT (1) LT2515870T (es)
MX (1) MX338323B (es)
MY (1) MY178169A (es)
NZ (1) NZ600627A (es)
PL (1) PL2515870T3 (es)
PT (1) PT2515870T (es)
RS (1) RS54953B1 (es)
RU (1) RU2561585C2 (es)
SG (1) SG181727A1 (es)
SI (1) SI2515870T1 (es)
SM (1) SMT201600277B (es)
TW (1) TWI548416B (es)
UA (1) UA108484C2 (es)
UY (1) UY33153A (es)
WO (1) WO2011076368A2 (es)
ZA (1) ZA201204522B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9707273B2 (en) 2013-03-01 2017-07-18 Fundació Hospital Universitari Vall D'hebron—Institut De Recerca Peptides for use in the topical treatment of retinal neurodegenerative diseases, in particular in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
GB201516066D0 (en) 2015-09-10 2015-10-28 Young & Co Llp D Treatment of retinitis pigmentosa
CN106822182A (zh) * 2016-12-27 2017-06-13 广州姿生生物科技有限公司 一种细胞提取物及其用途
WO2018143911A1 (en) 2017-01-31 2018-08-09 Kimberly-Clark Worldwide, Inc. Antibacterial composition including benzoic acid ester and methods of inhibiting bacterial growth utilizing the same
WO2018211526A1 (en) * 2017-05-15 2018-11-22 Sun Pharmaceutical Industries Limited Octreotide injection
JP7470791B2 (ja) * 2019-11-21 2024-04-18 サムジン ファーマシューティカル カンパニー，リミテッド 眼疾患の予防または治療用点眼組成物
KR20230133595A (ko) * 2022-03-11 2023-09-19 한국한의약진흥원 등검은말벌독에 함유된 세로토닌의 안정성을 유지하기 위한 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182258A (en) 1989-03-20 1993-01-26 Orbon Corporation Systemic delivery of polypeptides through the eye
WO1999024019A1 (en) * 1997-11-06 1999-05-20 Orbon Corporation Stabilized, dry pharmaceutical compositions for drug delivery and methods of preparing same
CA2263042A1 (en) * 1999-02-25 2000-08-25 Robert W.A. Kuijpers Treatment of edema
EP1040837A3 (en) 1999-02-26 2002-01-02 Erasmus Universiteit Rotterdam Medicaments for the treatment of a choroidal neovascularization (CNV) related disorder
AU2001283957A1 (en) 2000-07-27 2002-02-13 Novartis Ag Treatment of ocular disorders with somatostatin analogues
TWI260228B (en) * 2002-12-31 2006-08-21 Ind Tech Res Inst Delivery carrier of presenting cell of somatostatin receptor
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US8871269B2 (en) 2003-07-15 2014-10-28 Evonik Corporation Method for the preparation of controlled release formulations
WO2007038687A2 (en) * 2005-09-27 2007-04-05 Aciont, Inc. Ocular administration of immunosuppressive agents
KR20100071984A (ko) * 2007-09-11 2010-06-29 몬도바이오테크 래보래토리즈 아게 치료제（들）로서의 ｌｖｖ―헤모르핀―６ 및 임의의 ａｆ１２１９８의 용도
EP2052716B1 (en) * 2007-10-24 2014-12-31 Camurus AB Controlled release formulations

Also Published As

Publication number Publication date
BR112012015386B1 (pt) 2021-02-23
IL220584A (en) 2016-10-31
HRP20160954T1 (hr) 2016-10-07
AU2010335595A1 (en) 2012-07-12
LT2515870T (lt) 2016-10-10
SMT201600277B (it) 2016-11-10
CN102753153A (zh) 2012-10-24
EP2515870A2 (en) 2012-10-31
MY178169A (en) 2020-10-06
SI2515870T1 (sl) 2016-09-30
UA108484C2 (en) 2015-05-12
PT2515870T (pt) 2016-08-29
CA2785104C (en) 2016-11-01
AR079683A1 (es) 2012-02-15
RU2561585C2 (ru) 2015-08-27
WO2011076368A2 (en) 2011-06-30
CA2785104A1 (en) 2011-06-30
HUE028193T2 (en) 2016-12-28
CO6592047A2 (es) 2013-01-02
ES2362604B1 (es) 2012-06-28
TWI548416B (zh) 2016-09-11
MX2012007282A (es) 2012-10-15
JP5920928B2 (ja) 2016-05-18
ES2362604A1 (es) 2011-07-08
WO2011076368A3 (en) 2012-03-15
JP2013515687A (ja) 2013-05-09
SG181727A1 (en) 2012-07-30
RS54953B1 (sr) 2016-11-30
ES2587828T3 (es) 2016-10-27
UY33153A (es) 2011-06-30
TW201141514A (en) 2011-12-01
ZA201204522B (en) 2013-09-25
US9216208B2 (en) 2015-12-22
NZ600627A (en) 2014-08-29
DK2515870T3 (en) 2016-09-05
RU2012126028A (ru) 2014-01-27
BR112012015386B8 (pt) 2021-05-25
CN102753153B (zh) 2015-11-25
KR20120120255A (ko) 2012-11-01
US20130210728A1 (en) 2013-08-15
IL220584A0 (en) 2012-08-30
CY1117854T1 (el) 2017-05-17
AU2010335595B2 (en) 2015-08-27
PL2515870T3 (pl) 2016-11-30
EP2515870B1 (en) 2016-05-25
CL2012001737A1 (es) 2012-11-16
KR101657737B1 (ko) 2016-09-19
HK1178049A1 (zh) 2013-09-06
BR112012015386A2 (pt) 2018-07-24

Similar Documents

Publication Publication Date Title
MX2011013060A (es) Formulaciones oftalmicas, metodos de preparacion y metodos para utilizarlas.
MY171920A (en) Prevention and treatment of ocular conditions
MY178169A (en) Topical ophthalmic peptide formulation
MX2009012645A (es) Formulaciones y metodos para tratar el ojo seco.
MX2021007268A (es) Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas.
EP4374873A3 (en) Methods for treating or preventing opthalmological conditions
EA200870396A1 (ru) Лечение аллергических заболеваний глаз
EP2424360A4 (en) TOPICAL, PERIOCULAR OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
WO2008029276A3 (en) Compositions and methods for the treatment of ophthalmic disease
WO2013186777A3 (en) Use of blocking agents of bone morphogenie protein (bmp) signaling for the treatment of neuroinflammatory and neurodegenerative diseases
ES2397889A1 (es) PÉPTIDOS MODULADORES DE PGC-1Alfa.
WO2012119070A3 (en) Silicone-based ophthalmic formulations
MX2014005209A (es) Un medicamento para tratar la enfermedad del ojo anterior que comprende rebamipida y un agente de retencion de lagrimas.
MX355770B (es) Composicion farmaceutica de ibuprofeno y tramadol para uso oftalmico.
IL273531A (en) Ophthalmic preparations containing latanoprost for use in the treatment of eye diseases
MX2016016090A (es) Composicion oftalmica para el tratamiento de infeccion ocular.
MX2017005522A (es) Tratamiento novedoso de la cornea usando laminina.
WO2013189606A3 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
WO2015048188A3 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX2019011925A (es) Conjugados y derivados de prostaglandina para tratar el glaucoma y la hipertension ocular.
EP3639854A4 (en) MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF
WO2017129577A8 (en) Ophthalmic gabapentin for the treatment of corneal ulcers
MX2015006779A (es) Proteina slurp-1 para usarse en el tratamiento de enfermedades oculares.
AU2014216273A8 (en) Topical ocular analgesic agents

Legal Events

Date Code Title Description
FG Grant or registration